Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix Therapeutics (Nasdaq: NRIX) announced the dosing of the first patient in its Phase 1a/1b trial for NX-5948, a selective degrader of Bruton’s tyrosine kinase (BTK), targeting relapsed B-cell malignancies. This open-label, dose escalation trial is ongoing across multiple UK centers, focusing on safety and tolerability. Initial data is expected in H2 2022. NX-5948 aims to address resistance seen with current BTK inhibitors. Nurix has four clinical trials running, with upcoming data catalysts anticipated over the next year.
Nurix Therapeutics, a clinical stage biopharmaceutical company (Nasdaq: NRIX), announced that CEO Arthur T. Sands will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 18th, 2022, at 11:00 a.m. ET. The event will be available via a live webcast and replay on the company's website. Nurix is focused on developing targeted protein modulation drugs through its DELigase platform, aimed at innovating cancer and other disease treatments.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) will host an R&D Day on May 26, 2022, from 8:00 a.m. to 11:00 a.m. ET in New York City. The event will feature Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center, discussing unmet needs in hematologic malignancies. Nurix's management will present updates on their four clinical programs and the DELigase® discovery platform. A live webcast will be available on their website.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) shared preclinical data at the AACR Annual Meeting, showcasing the potential of investigative therapies NX-2127 and DeTIL-0255 for treating B-cell malignancies and solid tumors. Key findings include NX-2127's unique ability to degrade Bruton’s tyrosine kinase (BTK) and IMiD neosubstrates, enhancing tumor cell killing. Additionally, NX-0255 was shown to enhance T-cell persistence and anti-tumor response in animal models. Nurix expects to provide clinical updates from both programs in H2 2022, following promising initial trial results.
Nurix Therapeutics (NRIX) reported encouraging developments, including the first patient dosed in the Phase 1 trial of DeTIL-0255, a drug-enhanced cell therapy for advanced gynecologic cancers. The company secured an Innovation Passport for NX-1607 from the UK for solid tumor treatment, facilitating faster market access. Financially, Nurix holds $385.7 million in cash and investments as of February 28, 2022, despite a net loss of $42.5 million for Q1 2022, compared to $24.3 million in Q1 2021. Collaboration revenue increased to $9.6 million, driven by milestones from Gilead and Sanofi.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced the dosing of its first patient in a Phase 1 clinical trial for DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy targeting advanced gynecological cancers. This therapy combines patient-derived TILs treated with NX-0255, a CBL-B inhibitor, developed through Nurix's DELigase platform. The study aims to assess safety and efficacy in ovarian, cervical, and endometrial cancer patients. Initial results are expected in the second half of 2022, representing a significant milestone in combining targeted protein modulation with cell therapy.
Nurix Therapeutics (Nasdaq: NRIX) announced that CEO Arthur T. Sands will join a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 2:15 PM ET. The session will be broadcast live and can be accessed via Nurix's website, with an archived version available for 30 days post-event. Nurix is focused on discovering and developing drugs that modulate protein levels to treat cancer and other diseases through its innovative platform targeting E3 ligases.
Nurix Therapeutics has received the Innovation Passport designation from the UK MHRA for its drug candidate NX-1607, aimed at treating advanced solid tumors. This designation supports Nurix's regulatory strategy, facilitating faster development and access to the Innovative Licensing and Access Pathway. NX-1607, an orally bioavailable inhibitor designed to enhance T-cell activation, is currently undergoing a Phase 1 trial. Initial pharmacokinetic and pharmacodynamic data is expected in mid-2022, indicating potential advancements in treatment options for solid tumor patients.
Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., the company's CEO, will participate in two key conferences in March 2022. The 32nd Annual Oppenheimer Healthcare Conference is scheduled for March 15 at 4:00 p.m. ET, and the 2nd Guggenheim Targeted Protein Degradation Day will take place on March 16 at 11:00 a.m. ET. Both events will be available via live webcast and archived on the Nurix website for 30 days.
Nurix Therapeutics (Nasdaq: NRIX) has announced that preclinical data for its NX-2127 and DeTIL-0255 programs will be showcased at the AACR Annual Meeting, scheduled from April 8-13, 2022, in New Orleans, LA. Key presentations include the impact of NX-0255 on T-cell anti-tumor activity and the tumor-killing mechanisms of NX-2127. The company is also advancing its Phase 1 clinical trials for both drug candidates, with patient dosing for DeTIL-0255 expected in the first half of 2022. Additional data updates are anticipated later in the year.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
